NEWS
- Biological Therapies for Myasthenia Gravis: FDA-Approved and Emerging Treatments
- Polyethylene Glycol (PEG) Hydrogel Based 3D Bioprinting
- Global Sales of Antibody-drug Conjugates (ADCs) in 2024
- Meet Us at TIDES USA 2025, Booth #913
- FDA Approves Datroway (Datopotamab Deruxtecan) in HR+/HER2– Breast Cancer
- Good News! mPEG-pALD (20K) Successfully Completed The FDA DMF Filing
- Celebrate Thanksgiving with 30% Off Monodispersed PEGs!
- Positive Trial Results of Semaglutide for MASH
- Claudin 18.2: A Promising New Target for Breakthrough Cancer Treatments
- Monodisperse (Discrete) PEGylation vs. Polydisperse PEGylation: Future Trends